系统性硬化症
Systemic sclerosis
定义 英文原文（暂无中文）
Systemic sclerosis (SSc) is a generalized disorder of small arteries, microvessels and connective tissue, characterized by fibrosis and vascular obliteration in the skin and organs, particularly the lungs, heart, and digestive tract. There are two main subsets of SSc: diffuse cutaneous SSc (dcSSc) and limited cutaneous SSc (lcSSc). A third subset of SSc has also been observed, called limited Systemic Sclerosis (lSSc) or systemic sclerosis sine scleroderma.
别名
系统性硬皮病
基本事实
- 遗传方式
- 多基因/多因素、不适用
- 发病年龄
- 成年期
- 患病率
- 1-5 / 10 000（Europe）
临床表型 86
极常见 99–80%7
- 胃肠道异常 HP:0011024
- 抗核抗体阳性 HP:0003493
- 关节疼痛 HP:0002829
- 皮肤硬化斑 HP:0031359
- 肌痛 HP:0003326
- 雷诺现象 HP:0030880
- 皮肤增厚 HP:0001072
常见 79–30%44
- 食管形态结构异常 HP:0002031
- 指（趾）骨关节形态异常 HP:0006261
- 肺间质形态异常 HP:0006530
- 肾脏异常 HP:0000077
- 肢端溃疡 HP:0006121
- 抗B23抗体阳性 HP:0034089
- 抗Ku抗体阳性 HP:0034088
- 抗PM-Scl抗体阳性 HP:0033560
- 抗PM-Scl100抗体阳性 HP:0034085
- 抗PM-Scl75抗体阳性 HP:0034086
- 抗RNA聚合酶Ⅲ自身抗体阳性 HP:0033038
- 抗Ro52/TRIM21抗体阳性 HP:0034093
- 抗RuvBL1/2抗体阳性 HP:0034090
- 抗Th/To抗体阳性 HP:0034081
- 抗U11/U12 RNP抗体阳性 HP:0034087
- 抗U3 RNP抗体阳性 HP:0034080
- 抗血管紧张素1型受体抗体阳性 HP:0034094
- 抗血管紧张素转换酶2抗体阳性 HP:0034117
- 抗双尾D2抗体阳性 HP:0034082
- 抗碳酸酐酶II抗体阳性 HP:0033394
- 抗着丝力蛋白A抗体阳性 HP:0034078
- 抗着丝力蛋白B抗体阳性 HP:0034079
- 抗A型内皮素受体抗体阳性 HP:0034095
- 抗核仁组织区抗体阳性 HP:0034083
- 抗血小板抗原抗体阳性 HP:4000170
- 抗血小板衍生生长因子受体 HP:0034091
- 抗拓扑异构酶 I 抗体阳性 HP:0030859
- 抗电压门控钾通道抗体阳性 HP:4000171
- 抗着丝粒抗体阳性 HP:0030873
- 皮肤钙质沉着症 HP:0025520
- 手指凹陷性疤痕 HP:0031293
- 指趾溃疡 HP:0031917
- 血清肌酸磷酸激酶升高 HP:0003236
- 手指肿胀 HP:0025131
- 不规则色素沉着 HP:0007400
- 关节肿胀 HP:0001386
- 肌无力 HP:0001324
- 甲床毛细血管扩张 HP:0001232
- 小口畸形 HP:0000160
- 疼痛 HP:0012531
- 肺纤维化 HP:0002206
- 指硬皮病 HP:0011838
- 点滴状色素减退 HP:0005590
- 毛细血管扩张 HP:0001009
偶见 29–5%34
- 大肠形态异常 HP:0002250
- 胃形态异常 HP:0002577
- 面部软组织异常 HP:0011799
- 小肠形态异常 HP:0002244
- 急性肾损伤 HP:0001919
- 蛋白尿 HP:0012592
- 脱发 HP:0001596
- 关节炎 HP:0001369
- Barrett食管 HP:0100580
- 大便失禁 HP:0002607
- 慢性肾病 HP:0012622
- 压迫性正中神经病变 HP:0012185
- 血管扩张 HP:0002617
- 吞咽困难 HP:0002015
- 呼吸困难 HP:0002094
- 屈曲挛缩 HP:0001371
- 胃食管反流 HP:0002020
- 胃肠道毛细血管扩张 HP:0002604
- 胃轻瘫 HP:0002578
- 肾小球肾炎 HP:0000099
- 少汗症 HP:0000966
- 间质性心脏纤维化 HP:0031329
- 肠道出血 HP:0002584
- 心肌炎 HP:0012819
- 指骨溶骨缺陷 HP:0009771
- 骨髓炎 HP:0002754
- 心包炎 HP:0001701
- 蛋白尿 HP:0000093
- 瘙痒 HP:0000989
- 肺动脉高压 HP:0002092
- 复发性皮肤感染 HP:0001581
- 肾功能不全 HP:0000083
- 右心衰竭 HP:0001708
- 晕厥 HP:0001279
罕见 <4–1%1
- 坏疽 HP:0100758
近两年的全球研究 7,626L2
2024/08 起在 Europe PMC 检索所得，按发表时间倒序显示最近 20 篇。标题未译成中文——自动翻译需要接入 LLM 服务，尚未引入。
- 2026-08Comment on "Distal radioulnar joint pseudotumoral calcinosis in scleroderma: A case report": when wrist calcinosis extends beyond soft tissues
- 2026-08A systematic review of abatacept and belatacept in immune-mediated diseases
- 2026-08Exhaled nitric oxide measurement in patients with connective tissue diseases associated with interstitial lung disease: a narrative review
- 2026-08Identification and quantification of alternative polyadenylation sites in single cell RNA-seq data using scPAISO
- 2026-08综述Scleroderma Renal Crisis in Mixed Connective Tissue Disease
- 2026-08Advanced imaging in systemic sclerosis: distinguishing activity from damage across organ systems
- 2026-08Hyper-aging in systemic sclerosis: linking genome instability, mitochondrial dysfunction, and inflammaging to fibrosis
- 2026-08综述Navigating evidence-based recommendations for the management of systemic sclerosis
- 2026-08Radiomics analysis and classification of esophageal involvement in systemic sclerosis using chest CT images
- 2026-08Investigation of Epigenetic Age Acceleration in Juvenile Scleroderma
- 2026-08Dynamic Individualized Prediction of Binary Clinical Outcomes Using Bayesian Generalized Linear Mixed Models With Application in Scleroderma
- 2026-08Vitamin B3 (Nicotinamide) Supplementation in Primary and Scleroderma-Related Raynaud Phenomenon
- 2026-08More Than Skin Deep: Moving From a Skin-Based Phenotypic Model to Molecular Classification of Systemic Sclerosis
- 2026-08Interleukin-40 in Systemic Sclerosis: A Treatment-Sensitive Marker of Immune Modulation Rather Than Disease Activity
- 2026-08Real-World Adherence to Systemic Sclerosis Quality Indicators: A Single-Center Quality of Care Study
- 2026-08When Infection Leaves Its Mark: Calcinosis in Systemic Sclerosis
- 2026-08Colonic Telangiectasias Associated With Systemic Sclerosis
- 2026-07病例报告Eclipsed Mitral Regurgitation: Paroxysmal Reversible Severe Mitral Regurgitation Presenting with Recurrent Pulmonary Edema: A Case Report
- 2026-07综述Cardiac Troponin in Autoimmune Rheumatic Diseases: Lights and Shadows
- 2026-07Adopting a Standard of Care for Systemic Sclerosis: The Mayo Clinic Experience
境外已获批用于本病的药物 2L2
欧盟 0 项、美国 2 项。同一药物在两地各批一次的，会分别列出。
「境外已获批」不等于「在中国能用」。中间隔着进口注册、临床急需境外新药通道、海南博鳌乐城国际医疗旅游先行区等几条路径，各有各的条件与费用。这一节能确定地告诉你的只有一件事：这个病在世界范围内已经有获得批准的药物，它叫什么名字。拿这个名字去问主治医生，是下一步最省力的做法。
药名一律保留英文原文，不作翻译——中国的药品通用名与英文名的音译经常不一致，译错会让人去找一个不存在的药。
已获孤儿药资格、尚未获批的在研药物（62 项）
孤儿药资格只是一种监管身份——它意味着监管机构认可这是罕见病用药并给予研发激励，不代表这个药已被证明有效，也不代表将来一定能上市。绝大多数最终不会成药。列在这里是为了看清有哪些方向正在被尝试。
- Peptide 144 TGF-beta1-inhibitor (TSLDASIIWAMMQN)欧盟2005-10-28Treatment of systemic sclerosis官方记录
- type I native bovine skin collagen欧盟2009-02-09Treatment of systemic sclerosis官方记录
- treprostinil diethanolamine欧盟2009-05-15Treatment of systemic sclerosis官方记录
- paquinimod欧盟2011-02-23Treatment of systemic sclerosis官方记录
- Humanised IgG1 monoclonal antibody against human eotaxin-2欧盟2014-11-19Treatment of systemic sclerosis官方记录
- nitroglycerin欧盟2015-02-12Treatment of systemic sclerosis官方记录
- autologous adipose tissue-derived stromal vascular fraction cells欧盟2015-03-19Treatment of systemic sclerosis官方记录
- 2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,欧盟2015-10-09Treatment of systemic sclerosis官方记录
- 2-[1-(3-{6-[(1E)-(hydroxyimino)methyl]-5-methyl-4-oxo-7-propyl-3H,4H-p欧盟2021-11-12Treatment of systemic sclerosis官方记录
- Efzofitimod欧盟2023-06-20Treatment of systemic sclerosis官方记录
- 2-(((2E)-3-(3-methoxy-4-(2-propyn-1-yloxy)phenyl)-1-oxo-2-propen-1-yl)欧盟2024-06-28Treatment of systemic sclerosis官方记录
- iloprost欧盟2025-06-20Treatment of systemic sclerosis官方记录
- resecabtagene autoleucel欧盟2025-11-21Treatment of systemic sclerosis官方记录
- upadacitinib欧盟2026-04-20Treatment of systemic sclerosis官方记录
- 8-methoxsalen美国1993-06-22For use in conjunction with the UVAR photopheresis to treat diffuse systemic sclerosis.官方记录
- Halofuginone美国2000-02-07Treatment of systemic sclerosis.官方记录
- peptide 144 TGF beta-1 inhibitor美国2006-04-27Treatment of systemic sclerosis官方记录
- Type 1 native bovine skin collagen美国2008-02-01Treatment of diffuse systemic sclerosis官方记录
- cyclophosphamide美国2011-06-07Treatment of systemic sclerosis.官方记录
- anifrolumab美国2013-10-16Treatment of systemic sclerosis官方记录
- pirfenidone美国2013-11-19Treatment of systemic sclerosis (including the associated interstitial lung disease)官方记录
- paquinimod美国2014-01-17Treatment of systemic sclerosis官方记录
- caprine hyperimmune serum against HIV lysate美国2014-02-14Treatment of systemic sclerosis官方记录
- monoclonal antibody targeting eotaxin-2美国2015-01-06Treatment of systemic sclerosis官方记录
- 1-(6-benzothiazolylsulfonyl)-5-chloro-1H-indole-2-butanoic acid美国2015-03-31Treatment of systemic sclerosis官方记录
- (6aR, 10aR)-3-(1â¿¿,1â¿¿-dimethylheptyl)-ο8-tetrahydro-cannabinol-9-c美国2015-06-10Treatment of systemic sclerosis官方记录
- (2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1h-pyrazolo [美国2015-10-14Treatment of systemic sclerosis.官方记录
- high molecular weight multimer of E3-Fc, an endostatin C-terminus and 美国2016-06-27Treatment of systemic sclerosis官方记录
- Autologous stromal vascular cell fraction from adipose tissue (central美国2016-11-09Treatment of impaired hand function due to systemic sclerosis官方记录
- (1'R,6'R)-3-(Benzylamine)-6-hydroxy-3'-methyl-4-pentyl-6'-(prop-1-en-2美国2017-07-06Treatment of systemic scleroderma (SSc)官方记录
- diosmin美国2018-05-15treatment of systemic sclerosis官方记录
- Anti-transforming growth factor beta (TGF-ß) trap fusion protein美国2019-03-25Treatment of systemic sclerosis.官方记录
- iloprost美国2019-05-09Treatment of systemic sclerosis官方记录
- Immune Globulin Intravenous (Human)美国2020-01-28Treatment of systemic sclerosis官方记录
- PEGylated recombinant human tumor necrosis factor-related apoptosis in美国2020-05-20Treatment of systemic sclerosis官方记录
- treprostinil美国2020-06-08Treatment of Systemic sclerosis官方记录
- Belumosudil美国2020-09-04Treatment of systemic sclerosis官方记录
- Homodimeric fragment crystallizable (Fc) fusion protein comprised of t美国2020-11-25Treatment of systemic sclerosis官方记录
- (2R,3S)-2-(3-(4,5-dichloro-1H-benzo[d]imidazol-1-yl)propyl)piperidin-3美国2021-05-20Treatment of systemic sclerosis官方记录
- cudetaxestat美国2021-10-12Treatment of systemic sclerosis.官方记录
另有 22 项未列出。
数据来自欧洲药品管理局（EMA）的药品与孤儿药资格公开导出表，以及美国 FDA 孤儿药资格数据库。两边口径不同：欧盟一侧取的是当前状态仍为「已授权」的药品；美国一侧记录的是「曾获批准」这一事实，FDA 的公开表不追踪药物此后是否退市（例如 Relyvrio 于 2024 年撤市，表中仍记为已获批）。请以官方记录页为准。
在中国开展的临床试验 92L2
按病名在 ClinicalTrials.gov 检索、并校验研究中心含中国大陆而来。登记状态不等于现在真的能入组——务必按 NCT 号到原站核实，并与主治医生商量。
登记为可入组 68
- 招募中NCT06417502Observational Study of Pediatric Rheumatic and Immunologic Diseases in China: The CAPRID Registry中国研究中心 9 个：Beijing、Changsha、Chongqing、Hangzhou、Nanjing、Shenzhen
- 仅邀请入组NCT05859997Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases中国研究中心 1 个：Shanghai
- 招募中NCT06056921Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease中国研究中心 1 个：Taiyuan
- 招募中NCT05878717A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease中国研究中心 11 个：Beijing、Changchun、Chengdu、Luzhou、Mianyang、Nanjing 等 11 地
- 招募中NCT06058091RY_SW01 Cell Injection Therapy in Systemic Sclerosis中国研究中心 1 个：Nanjing
- 招募中NCT06189495A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease中国研究中心 4 个：Beijing、Chengdu、Jinan、Wuhan
- 招募中NCT06249438A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy中国研究中心 1 个：Shanghai
- 招募中NCT06503224An Exploratory Clinical Study of SCAR02 Targeting BCMA and CD19 for the Treatment of Refractory Autoimmune Diseases中国研究中心 1 个：Changsha
- 招募中NCT06379646An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease中国研究中心 1 个：Shanghai
- 尚未开始招募NCT06420154The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases中国研究中心 1 个：Wenzhou
- 招募中NCT06546540The Safety and Efficacy of Telitacicept in the Treatment of Systemic Sclerosis中国研究中心 1 个：Beijing
- 招募中NCT06414135Relmacabtagene Autoleucel for the Treatment of Systemic Sclerosis中国研究中心 1 个：Shanghai
- 招募中NCT06350110Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)中国研究中心 1 个：Beijing
- 招募中NCT06548607Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases中国研究中心 1 个：Bengbu
- 招募中NCT06470048A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis中国研究中心 7 个：Beijing、Changchun、Chengdu、Nanning、Ningbo、Tianjin 等 7 地
- 招募中NCT06888960Safety Study of CC312 in Autoimmune Disease Patients中国研究中心 1 个：Tianjin
- 招募中NCT06716606A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)中国研究中心 2 个：Beijing、Zhuzhou
- 招募中NCT06792344Clinical Study of CD19 CAR-T in the Treatment of Refractory Systemic Sclerosis中国研究中心 1 个：Hangzhou
- 招募中NCT06794008BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases中国研究中心 1 个：Beijing
- 招募中NCT06775912Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases中国研究中心 1 个：Lianyungang
- 招募中NCT06614270Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases中国研究中心 1 个：Hangzhou
- 招募中NCT06375005Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis中国研究中心 9 个：Hangzhou、Huzhou、Jiaxing、Ningbo、Shanghai、Wenzhou 等 7 地
- 招募中NCT06941129CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases中国研究中心 1 个：Tianjin
- 招募中NCT06822881CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc)中国研究中心 1 个：Beijing
- 招募中NCT06801119Efficacy and Safety of HN2301 in Autoimmune Diseases（AIDs）中国研究中心 1 个：Hefei
另有 43 项未列出。
其他状态的试验（24 项）
- 已终止NCT00706082Early, Simple and Reliable Detection of Pulmonary Arterial Hypertension (PAH) in Systemic Sclerosis (SSc)中国研究中心 1 个：Beijing
- 状态未知NCT00962923Allogeneic Mesenchymal Stem Cells Transplantation for Systemic Sclerosis (SSc)中国研究中心 1 个：Nanjing
- 已完成NCT02597933A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis中国研究中心 9 个：Beijing、Changchun、Chengdu、Hefei、Shanghai、Shenyang 等 7 地
- 状态未知NCT03068234Pirfenidone as Treatment of Skin Fibrosis in Systemic Sclerosis中国研究中心 1 个：Shanghai
- 状态未知NCT03446339Pulmonary Hypertension Screening for Rheumatology Patients (SOPHIE)中国研究中心 1 个：Hong Kong
- 已完成NCT03313180A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis中国研究中心 6 个：Beijing、Changchun、Chengdu、Hefei、Shanghai、Shenyang
- 状态未知NCT03856853Efficacy and Safety of Pirfenidone in Patient With Systemic Sclerosis-associated Interstitial Lung Disease中国研究中心 1 个：Beijing
- 状态未知NCT04928586Immunosuppressant Combined With Pirfenidone in CTD-ILD中国研究中心 1 个：Jinan
- 状态未知NCT05297474Structural and Functional Impairment of Multiple Organs in Patients With Systemic Sclerosis: A MR Imaging Study中国研究中心 2 个：Beijing
- 状态未知NCT05085444A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma中国研究中心 1 个：Hangzhou
- 进行中·不再招募NCT05300932A Study Evaluating the Efficacy and Safety of Baricitinib in Systemic Sclerosis中国研究中心 2 个：Wuhan
- 状态未知NCT05505409Efficacy and Safety of Pirfenidone in CTD-ILD中国研究中心 1 个：Jinan
- 已完成NCT05559580A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms中国研究中心 16 个：Beijing、Bengbu、Changchun、Chengdu、Guangzhou、Hangzhou 等 13 地
- 进行中·不再招募NCT06025578A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis中国研究中心 45 个：Beijing、Changsha、Chengdu、Guangzhou、Hangzhou、Hefei 等 27 地
- 状态未知NCT06316076Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases中国研究中心 1 个：Shanghai
- 进行中·不再招募NCT05925803Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)中国研究中心 6 个：Beijing、Guangzhou、Hangzhou、Lanzhou、Shanghai、Tianjin
- 状态未知NCT06149260Subcutaneous Semaglutide in Systemic Scleroderma中国研究中心 1 个：Changsha
- 状态未知NCT06361745Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases中国研究中心 1 个：Hefei
- 状态未知NCT06373081Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease中国研究中心 1 个：Shanghai
- 已撤回NCT06548620A Study of RD06-04 in Patients With Active Autoimmune Diseases中国研究中心 1 个：Zhengzhou
- 已暂停NCT06549296Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune Diseases中国研究中心 1 个：Xuzhou
- 进行中·不再招募NCT07155369UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases中国研究中心 1 个：Xuzhou
- 已撤回NCT06866080A Study of LCAR-AIO in Subjects With Relapsed/Refractory Autoimmune Diseases中国研究中心 4 个：Hefei、Nanjing、Wenzhou、Xuzhou
- 已暂停NCT07527936A Study of BEN301 Injection in theTreatment of Autoimmune Diseases中国研究中心 1 个：Shanghai
中国境外的在招试验 228L2
这些试验在中国没有研究中心，通常无法直接报名——入组一般要求在当地居住并接受随访。列在这里是因为它另有用处：看清楚全世界正在试哪些药、做到了哪一期、由谁在做。把药名和 NCT 编号记下来去问主治医生，或据此进一步查该药是否已在境外获批、是否有拓展性用药（expanded access）通道。
美国41法国37西班牙13土耳其10加拿大10意大利9英国9德国9澳大利亚7以色列6波兰6罗马尼亚6比利时5巴西5另有 32 个国家/地区
CT.gov 报告命中 228 项，此处取回并展示最近的 15 项。
- 尚未开始招募NCT07209644Catestatin as a Novel Biomarker for Cardiovascular and Microvascular Involvement in Systemic Sclerosis
- 尚未开始招募NCT07748000A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon Attacks
- 尚未开始招募NCT07649265A Trial in Healthy Adult Participants and Adults With Autoimmune Disease to Test How HBM7020 is Tolerated and Absorbed in the Body
- 尚未开始招募NCT07717060Extracellular Vesicle Dynamics Predicting Vascular Complications and Treatment Response in Systemic Sclerosis
- 尚未开始招募NCT07642297TL1A Inhibition in Systemic Sclerosis-Related Skin Fibrosis and Immunological Alterations: A Proof-of-Concept In Vitro Study (FIBROSTOP)意大利
- 尚未开始招募NCT07697274Hyaluronidase for Sclerodactyly in Systemic Sclerosis Trial美国
- 尚未开始招募NCT07544225Study Investigating the Safety of Anti-CD19 CAR-T Cells Therapy Produced at Gustave Roussy for Adults With Severe and Refractory Systemic Autoimmune Rheumatic Diseases法国
- 尚未开始招募NCT07691970Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment奥地利、比利时、巴西、保加利亚、法国、希腊、印度、以色列 等 22 国
- 尚未开始招募NCT07650565Tissue Modeling in Systemic Sclerosis Using Induced Pluripotent Stem Cells (iPSCs)法国
- 尚未开始招募NCT07335562A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis比利时、加拿大、法国、德国、意大利、日本、西班牙、瑞士 等 10 国
- 尚未开始招募NCT07759557Efficacy of A Non-Invasive Botulinum Toxin Microneedle Pad for the Treatment of Secondary Raynaud's Phenomenon
- 尚未开始招募NCT07490275Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases
- 招募中NCT06708845US Zamto-cel Autoimmune Diseases美国
- 招募中NCT07493395Phase IIa Trial of Anti-CD19 CAR T-Cells in Systemic Sclerosis Resistant to Immunosuppressive Therapy法国
- 招募中NCT07543679Objective Assessment of Skin Damage Using ADHELASKIN in Patients With Systemic Sclerosis法国
外部标识与链接
OrphanetOMIM:181750MONDO:0005100GARD:9748ICD-10 M34.0、M34.1、M34.2、M34.8ICD-11 4A42ClinicalTrials.gov 检索
发现这一页有错误？告诉我 · 邮件主题会自动带上本页的 ORPHA 编号
本页数据来源
- 疾病定义、同义词、基因、表型、流行病学：Orphanet（CC BY 4.0）
- 中文病名：Orphanet 中文包，冻结于 2020-06-01
- 表型中文标签：HPO 简体中文翻译（CHPO 上游成果）